Company intelligence / Profile preview
Tay Therapeutics
Dundee, Scotland, United Kingdom
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
VYNE Therapeutics has dosed first participants in Phase 1a trial of VYN202 (BD2-Selective BET Inhibitor) and Phase 2b Vitiligo Trial of VYN201
- Therapeutic areas
- Metabolic DisordersRare DiseasesImmunologyEndocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
VYNE Therapeutics (NASDAQ-listed biotech)Almirall (licensing discussion for topical eczema)
Beyond the preview
Go deeper on Tay Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tay Therapeutics.